Predictors of pathological complete response to neoadjuvant chemotherapy in XXXX : The impact of chemotherapeutic regimen.

@entity1 @entity0 @entity5 @entity5948 @entity3907 @entity1722 @entity34
UNASSIGNED: In this study, we sought to determine the predictors of pathological complete response (pCR) and compare the chemotherapeutic regimens administered to @entity0 @entity1 with and those without pCR. We retrospectively reviewed the data of 879 @entity1 treated at the Alvin J. Siteman @entity5 Center between 2006 and 2010, to identify @entity1 who were diagnosed with primary @entity0 and received neoadjuvant chemotherapy. @entity1 who received only neoadjuvant endocrine therapy were considered to be ineligible. @entity1 , @entity5 , and treatment characteristics, including type of chemotherapy, were compared between @entity1 who did and those who did not achieve pCR using Chi-square or Fishers exact tests and multivariate logistic regression analysis. Two-sided P-values of <0.05 were considered significant. Of the 333 @entity1 who met the inclusion criteria, 61 (18.3%) had documented pCR. Compared with @entity1 not achieving pCR, a greater proportion of @entity1 with pCR had @entity34 (80.3 vs. 68%, P=0.057), had poorly differentiated (grade 3) @entity5 (82 vs. 59.2%, P<0.001), had negative lymph node involvement (41 vs. 34%, P=0.0004) and had @entity5 that were @entity1722 -amplified (41 vs. 23.5%, P=0.0054). A greater proportion of @entity1 with pCR received @entity3907 -based chemotherapy (23 vs. 12.5%, P=0.016) or trastuzumab in conjunction with chemotherapy (41.0 vs. 16.9%, P<0.001). No @entity1 receiving solely @entity5948 -based therapy achieved pCR in our study. Our study demonstrated that, for @entity0 , lower stage, negative lymph node involvement and @entity1722 receptor amplification were each associated with pCR. @entity3907 therapy and the concurrent use of trastuzumab were also associated with a higher likelihood of pCR.
